Upexi Valuation
Is UPXI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of UPXI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate UPXI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate UPXI's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UPXI?
Key metric: As UPXI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is UPXI's PS Ratio? | |
|---|---|
| PS Ratio | 0.05x |
| Sales | US$83.98m |
| Market Cap | US$4.08m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | -8.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does UPXI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
SISI Shineco | 0.3x | n/a | US$3.3m |
FLGC Flora Growth | 0.3x | 8.2% | US$17.5m |
HYEX Healthy Extracts | 2.1x | n/a | US$3.6m |
LIFD LFTD Partners | 0.2x | n/a | US$8.5m |
UPXI Upexi | 0.05x | -13.5% | US$4.1m |
Price-To-Sales vs Peers: UPXI is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does UPXI's PS Ratio compare vs other companies in the US Personal Products Industry?
Price-To-Sales vs Industry: UPXI is good value based on its Price-To-Sales Ratio (0x) compared to the US Personal Products industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is UPXI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.05x |
| Fair PS Ratio | 0.1x |
Price-To-Sales vs Fair Ratio: UPXI is good value based on its Price-To-Sales Ratio (0x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Beauty Health
US$194.3m
Designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide.
SKIN
US$1.62
7D
-5.0%
1Y
-27.4%
Reynolds Consumer Products
US$5.8b
Produces and sells products in cooking, waste and storage, and tableware product categories in the United States and internationally.
REYN
US$27.57
7D
-0.2%
1Y
3.8%
Unicharm
JP¥2.3t
Engages in the manufacturing and sale of wellness, feminine, baby and children, kirei, and pet care products in Japan and internationally.
UNCH.F
JP¥24.20
7D
-4.1%
1Y
-22.6%